Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”

A recent study by Zimmerman et al. (2023) reported non-significant higher relative vaccine effectiveness of recombinant (RIV4) over the standard-dose influenza vaccines (SDIV) against outpatient illness during the 2018–19 and 2019–20 vaccination seasons. We agree with the authors’ conclusions and wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadigal, Sanjay, Colombo, Laura, Haughie, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Influenza
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288927/
https://www.ncbi.nlm.nih.gov/pubmed/37344371
http://dx.doi.org/10.1080/21645515.2023.2227034
_version_ 1785062175120818176
author Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
author_facet Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
author_sort Hadigal, Sanjay
collection PubMed
description A recent study by Zimmerman et al. (2023) reported non-significant higher relative vaccine effectiveness of recombinant (RIV4) over the standard-dose influenza vaccines (SDIV) against outpatient illness during the 2018–19 and 2019–20 vaccination seasons. We agree with the authors’ conclusions and would like to emphasize minimal difference between RIV4 and SDIV using Number Needed to Vaccinate (NNV). The NNV analysis showed 8.9 for the RIV4 and 10 for the SDIV in the 50–64 age group. In the 65+ age group, the NNV was 10.6 for the RIV4 and 11.4 for the SDIV. This indicates a minimal difference between both vaccines and hence they both can be used in immunization programs to improve vaccine coverage.
format Online
Article
Text
id pubmed-10288927
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102889272023-06-24 Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design” Hadigal, Sanjay Colombo, Laura Haughie, Scott Hum Vaccin Immunother Influenza A recent study by Zimmerman et al. (2023) reported non-significant higher relative vaccine effectiveness of recombinant (RIV4) over the standard-dose influenza vaccines (SDIV) against outpatient illness during the 2018–19 and 2019–20 vaccination seasons. We agree with the authors’ conclusions and would like to emphasize minimal difference between RIV4 and SDIV using Number Needed to Vaccinate (NNV). The NNV analysis showed 8.9 for the RIV4 and 10 for the SDIV in the 50–64 age group. In the 65+ age group, the NNV was 10.6 for the RIV4 and 11.4 for the SDIV. This indicates a minimal difference between both vaccines and hence they both can be used in immunization programs to improve vaccine coverage. Taylor & Francis 2023-06-21 /pmc/articles/PMC10288927/ /pubmed/37344371 http://dx.doi.org/10.1080/21645515.2023.2227034 Text en © 2023 Viatris. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Influenza
Hadigal, Sanjay
Colombo, Laura
Haughie, Scott
Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title_full Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title_fullStr Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title_full_unstemmed Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title_short Reply letter to “Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
title_sort reply letter to “vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018–2019 and 2019–2020 calculated using a retrospective test-negative design”
topic Influenza
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288927/
https://www.ncbi.nlm.nih.gov/pubmed/37344371
http://dx.doi.org/10.1080/21645515.2023.2227034
work_keys_str_mv AT hadigalsanjay replylettertovaccineeffectivenessofrecombinantandstandarddoseinfluenzavaccinesagainstoutpatientillnessduring20182019and20192020calculatedusingaretrospectivetestnegativedesign
AT colombolaura replylettertovaccineeffectivenessofrecombinantandstandarddoseinfluenzavaccinesagainstoutpatientillnessduring20182019and20192020calculatedusingaretrospectivetestnegativedesign
AT haughiescott replylettertovaccineeffectivenessofrecombinantandstandarddoseinfluenzavaccinesagainstoutpatientillnessduring20182019and20192020calculatedusingaretrospectivetestnegativedesign

Ejemplares similares